Viral Vector Packaging Services Market Report 2026

The viral vector packaging services market size has grown rapidly in recent years. It will grow from $1.68 billion in 2025 to $1.94 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to expansion of gene therapy clinical trials, increasing demand for viral vectors in vaccine research, early investments in cell and gene therapy manufacturing, growth of academic and translational research, availability of contract manufacturing services.

The viral vector packaging services market size is expected to see rapid growth in the next few years. It will grow to $3.42 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to increasing commercialization of gene therapies, rising investments in advanced biologics manufacturing, expansion of personalized medicine pipelines, growing demand for scalable vector production, increasing regulatory approvals for gene-based treatments. Major trends in the forecast period include expansion of large-scale viral vector manufacturing capacity, rising demand for gmp-grade viral vectors, growing adoption of standardized packaging protocols, increased focus on scalable production platforms, enhanced emphasis on regulatory-compliant vector manufacturing.

The growing demand for gene therapies is expected to drive the expansion of the viral vector packaging services market in the coming years. Gene therapies are treatments that involve adding, removing, or modifying genetic material in a patient’s cells to prevent or treat diseases. This demand is rising due to improvements in delivery systems, which allow safe, efficient, and targeted transport of genetic material into cells. Viral vector packaging services support gene therapy development by supplying ready-to-use, high-quality viral vectors, making them crucial for reliable and effective genetic material delivery. They help shorten development timelines and reduce production bottlenecks by offering comprehensive solutions, facilitating the creation of advanced therapeutics and research tools. For example, in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, reported that the Food and Drug Administration (FDA) approved six gene therapy products in 2023, up from five in 2022. Consequently, the rising demand for gene therapies is fueling the growth of the viral vector packaging services market.

Key players in the viral vector packaging services market are emphasizing the development of technologically advanced solutions, such as lentiviral vector packaging systems, to improve efficiency, enhance reliability, and shorten development timelines. Lentiviral vector packaging systems are tools and processes designed to produce lentiviral vectors that safely deliver genetic material into target cells for research and gene therapy applications. For instance, in June 2023, Charles River Laboratories International Inc., a US-based contract research organization (CRO), introduced off-the-shelf lentiviral vector (LVV) packaging plasmids. This launch provides gene therapy developers with ready-to-use plasmid components that help reduce development timelines and production bottlenecks, while supporting more efficient and cost-effective lentiviral vector manufacturing. These offerings are further strengthened by viral vector production services, covering the process from clone construction to GMP-grade manufacturing for clinical and commercial use.

In December 2023, Ajinomoto Co. Inc., a Japan-based food and biotechnology company, acquired Forge Biologics Holdings LLC for an undisclosed sum. Through this acquisition, Ajinomoto aims to combine its AminoScience technology platform with Forge’s gene therapy CDMO capabilities to accelerate rare disease treatment innovation, expand its presence in advanced healthcare sectors, and transition toward a high-value-added business model for sustained growth. Forge Biologics Holdings LLC is a US-based contract development and manufacturing organization (CDMO) that specializes in viral vector packaging services.

Major companies operating in the viral vector packaging services market are Novartis AG, Thermo Fisher Scientific Inc., Lonza Group AG, Charles River Laboratories International Inc., Catalent Inc., Takara Bio Inc., Aldevron LLC, FUJIFILM Diosynth Biotechnologies Inc., Oxford Biomedica PLC, OriGene Technologies Inc., Applied Biological Materials Inc., PackGene Co. Ltd., VectorBuilder Inc., ProMab Biotechnologies Inc., System Biosciences LLC (SBI), SignaGen Laboratories Inc., Cellecta Inc., Cell Biolabs Inc., WZ Biosciences Inc., Creative Biogene Co. Ltd.

North America was the largest region in the viral vector packaging services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector packaging services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vector packaging services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the viral vector packaging services market by increasing costs of imported bioprocessing equipment, single-use consumables, plasmid DNA materials, and quality testing instruments required for vector production. Service providers in North America and Europe are particularly affected due to reliance on specialized imported inputs, while Asia-Pacific faces higher costs for scaling GMP manufacturing facilities. These tariffs are raising operational expenses and extending production timelines for clinical and commercial batches. However, they are also encouraging domestic sourcing of bioprocess materials, localized manufacturing investments, and regional expansion of viral vector packaging capabilities to strengthen supply chain resilience.

The viral vector packaging services market research report is one of a series of new reports that provides viral vector packaging services market statistics, including viral vector packaging services industry global market size, regional shares, competitors with a viral vector packaging services market share, detailed viral vector packaging services market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector packaging services industry. This viral vector packaging services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral vector packaging services are specialized processes that produce viruses engineered to deliver genetic material into target cells safely and efficiently. They generate high-quality, functional viral vectors for applications such as gene therapy, vaccine development, and biomedical research. These services facilitate the development of advanced therapeutics and research tools, ensuring scalable production to meet clinical and commercial demands while complying with strict safety and regulatory standards.

The main service types of viral vector packaging services include contract development and manufacturing services, custom viral vector production, ready-to-use viral vectors, and quality control and testing services. Contract development and manufacturing services involve outsourcing the design, development, and production of viral vectors to specialized companies on behalf of clients, typically in the pharmaceutical, biotechnology, or related industries. These services cover vector types such as adenoviral vectors, lentiviral vectors, adeno-associated viral (AAV) vectors, and retroviral vectors, using technologies including transfection-based methods, packaging systems, viral packaging cell lines, and purification techniques. Production scales range from small to large, and end users include gene therapy, cell therapy, vaccination, and research and development sectors.

The viral vector packaging services market includes revenues earned by entities through vector design and optimization, cell line engineering, upstream processing, downstream purification, fill and finish services, stability testing, and sterility testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.